Screener
Crinetics Pharmaceuticals CRNX Business Segments — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Revenue: | ||
| Product revenue, net | $10,306 | — |
| Collaboration and license revenue | 428 | 361 |
| Total revenue | 10,734 | 361 |
| Less: | ||
| Cost of product revenue | (200) | — |
| Research and development | ||
| Paltusotine | (11,869) | (17,251) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's business segments — total revenue?
- Crinetics Pharmaceuticals (CRNX) reported business segments — total revenue of $10.73M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — total revenue changed year-over-year?
- Crinetics Pharmaceuticals's business segments — total revenue increased by 2873.4% year-over-year, from $361K to $10.73M.
- What does business segments — total revenue mean?
- This metric represents the total net revenue generated by the company's primary business segment from the sale of pharmaceutical products. It reflects the company's ability to successfully commercialize its therapeutic assets and generate top-line growth. Monitoring this figure is essential for assessing market adoption and the transition from clinical-stage development to commercial operations.
Ask your AI about Crinetics Pharmaceuticals's business segments — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude